Pharmaceuticals

Teva's new once-monthly olanzapine injection could revolutionize schizophrenia care in Europe, offering hope for better treatment adherence and patient outcomes.

With regulations easing and patient demand soaring, Europe's medical cannabis market is exploding. Canadian firms are racing to stake their claim.

A new guide from QAD | Redzone challenges manufacturers to ditch AI hype and adopt a disciplined, CFO-led approach focused on measurable financial outcomes.

A potential first-in-class antibody-drug conjugate for colorectal cancer begins a pivotal trial, aiming to help patients who have run out of options.

By hiring a third former FDA oncology leader, Precision for Medicine creates an unparalleled regulatory brain trust to speed up cancer drug approvals.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

A landmark advocacy effort secures official recognition for clinical research professionals, shining a light on a workforce facing critical shortages and burnout.

With its latest purchase, Harbor IT expands into the Southeast, targeting life sciences and manufacturing with a highly specialized service model.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

F1 star Sergio Pérez and Mexican lab Biofarma launch a new supplement line, betting on celebrity power, scientific claims, and a new CSR commitment.

New data shows automated systems are slashing drug approval times and saving patients millions, offering a glimpse into a future with fewer healthcare hurdles.

Paris-based Ennov lands a major transatlantic investment to accelerate its AI platform, aiming to reshape global drug development and regulatory processes.

A novel drug is in clinical trials for depression, moving beyond neurotransmitters to target the brain's fundamental energy production and repair mechanisms.

ZoomRx's new AI operating system, Sagan Agents, promises to slash market research timelines from weeks to days, reshaping strategic insights for biopharma.

A new partnership embeds Eli Lilly's powerful AI models into CDD Vault, giving smaller biotechs unprecedented access to big pharma's discovery tools.

IGI announces ISB 2301, a first-in-class antibody targeting three tumor antigens and activating both T and NK cells for a new assault on solid tumors.

A first-in-class drug for anxiety has entered patient trials, offering a novel approach that could reshape mental healthcare for millions.

Two specialist investors are merging to create the world's largest dedicated healthcare fund, aiming to reshape global health innovation from West to East.

Led by OrbiMed, the financing will propel Accro's promising oral RIPK2 inhibitor for Ulcerative Colitis into a pivotal Phase IIb clinical trial.